Open AccessTreatment of pituitary dwarfism in children and teenagers in the Stavropol territory
Author(s) -
Leonid Klimov,
Roza Atanesyan,
Tatyana A. Uglova,
Т. М. Вдовина,
Viktoria Alexandrovna Kuryaninovna,
Marina Stoyan,
Svetlana Dolbnya,
Lilit Samvelovna Alaverdyan,
Rafael Isaakovich Arakelyan,
Elena Semenovna Slavickaya,
Elena Otarievna Demurcheva,
Tatyana Boleslavovna Semenova
Publication year - 2016
Publication title -
problems of endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.124
H-Index - 5
eISSN - 2308-1430
pISSN - 0375-9660
DOI - 10.14341/probl201662110-15
Subject(s) - dwarfism , medicine , somatotropic cell , anthropometry , growth hormone , endocrinology , pediatrics , growth hormone deficiency , hormone , biology , biochemistry , gene
The article is devoted to the analysis of clinical and anthropometric indicators of 38 children and adolescents with pituitary dwarfism in the Stavropol region, receiving replacement therapy with recombinant growth hormone (rGH). The authors demonstrated a high growth stimulating efficacy of the rGR, as well as a positive impact on the level of blood cholesterol in children with somatotropic deficiency. Prognostic factors influencing the effectiveness of treatment were found (chronological age of initiation of therapy, baseline SDS of growth). In particular, it is shown that therapy with preparations of GH in children aged 8 to 10 years allows you to achieve a higher growth-stimulating effect in comparison with patients whose treatment is carried out at a later age. The study of the relationship between the initial deviation of the length of the body and the results of therapy in patients with growth hormone deficiency illustrates that a pronounced lag in growth is a predictive factor provides a more significant effect drugs rGR.